Transition to dolutegravir-based ART in 35 low- and middle-income countries: a global survey of HIV care clinics.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zaniewski Elizabeth, Skrivankova Veronika Whitesell, Brazier Ellen, Avihingsanon Anchalee, Wagner Cardoso Sandra, Cesar Carina, Chenal Henri, Crabtree-Ramírez Brenda E, Ditangco Rossana A, Ebasone Peter Vanes, Eley Brian, Euvrard Jonathan George, Fatti Geoffrey, Huwa Jacqueline Madalitso, Lelo Patricia, Machado Daisy Maria, Messou Eugene Kouassi, Minga Albert Kla, Muleebwa Joseph, Mundhe Sanjay, Murenzi Gad, Muyindike Winnie R, Nsonde Dominique Mahambou, Obatsa Sarah M, Odhiambo Joseph, Prozesky Hans Walter, Rungmaitree Supattra, Semeere Aggrey Semwendero, Seydi Moussa, Sipambo Nosisa, Sudjaritruk Tavitiya, Technau Karl-Günter, Tiendrebeogo Thierry, Twizere Christelle, Ballif Marie
Аннотация
DESIGN: Site-level survey conducted in 2020-2021 among HIV clinics in low- and middle-income countries (LMICs).
METHODS: We assessed the status of dolutegravir rollout and viral load and drug resistance testing practices for persons on ART switching to dolutegravir-based regimens. We used generalized estimating equations to assess associations between clinic rollout of both first- and second-line dolutegravir-based ART regimens (dual rollout) and site-level factors.
RESULTS: Of 179 surveyed clinics, 175 (98%) participated; 137 (78%) from Africa, 30 (17%) from the Asia-Pacific, and 8 (5%) from Latin America. Most clinics (80%) were in low- or lower-middle-income countries, and there were a mix of primary-, secondary- and tertiary-level clinics. Ninety percent reported rollout of first-line dolutegravir, 59% of second-line, 94% of first- or second-line and 55% of dual rollout. The adjusted odds of dual rollout were higher among tertiary-level [adjusted odds ratio (aOR) 4.00; 95% confidence interval (CI) 1.39-11.47] and secondary-level clinics (aOR 3.66; 95% CI 2.19-6.11) than in primary-level clinics. Over half (59%) of clinics that introduced first- or second-line dolutegravir-based ART required recent viral load testing before switching to dolutegravir, and 15% performed genotypic resistance testing at switch.
CONCLUSIONS: Dolutegravir-based ART was rolled out at nearly all IeDEA clinics in LMICs, yet many switched persons to dolutegravir without recent viral load testing and drug resistance testing was rarely performed. Without such testing, drug resistance among persons switching to dolutegravir may go undetected.